Formulation for topical non-invasive application in vivo

Details Formulation for topical non-invasive application in vivo Formulation for topical non-invasive application in vivo

2007-02-13

2007-02-13

Hoffman, Susan Coe (Department: 1655)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Cosmetic, antiperspirant, dentifrice

C424S450000

Reexamination Certificate

active

09887493

ABSTRACT:
A formulation comprising molecular arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of said pores is smaller than the average penetrant diameter, provided that the penetrants can transport agents or else enable agent permeation through the pores after penetrants have entered pores, characterized in that the formulation comprises at least one consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over, and retention at, the application area is enabled and/or at least one antioxidant in an amount that reduces the increase of oxidation index to less than 100% per 6 months and/or at least one microbicide in an amount that reduces the bacterial count of 1 million germs added per g of total mass of the formulation to less than 100 in the case of aerobic bacteria, to less than 10 in the case of entero-bacteria, and to less than 1 in the case ofPseudomonas aeruginosaorStaphilococcus aureus, after a period of 4 days.

REFERENCES:
patent: 4333927 (1982-06-01), Ofuchi et al.
patent: 4427670 (1984-01-01), Ofuchi et al.
patent: 4619794 (1986-10-01), Hauser
patent: 4814161 (1989-03-01), Jinks et al.
patent: 4911928 (1990-03-01), Wallach
patent: 4921706 (1990-05-01), Roberts et al.
patent: 4937078 (1990-06-01), Mezei et al.
patent: RE33273 (1990-07-01), Speaker
patent: 4944948 (1990-07-01), Uster et al.
patent: 4954345 (1990-09-01), Müller
patent: 5238613 (1993-08-01), Anderson
patent: 5322685 (1994-06-01), Nakagawa et al.
patent: 5607692 (1997-03-01), Ribier et al.
patent: 5741515 (1998-04-01), Ciceri et al.
patent: 5958379 (1999-09-01), Regenold et al.
patent: 6562370 (2003-05-01), Luo et al.
patent: 6582724 (2003-06-01), Hsu et al.
patent: 6586000 (2003-07-01), Luo et al.
patent: 6645520 (2003-11-01), Hsu et al.
patent: 6835392 (2004-12-01), Hsu et al.
patent: 2002/0048596 (2002-04-01), Cevc
patent: 1740283 (1983-07-01), None
patent: 724218 (1996-10-01), None
patent: 1 143 656 (1983-03-01), None
patent: 1289420 (1991-09-01), None
patent: 2052164 (1992-09-01), None
patent: 3016976 (1980-11-01), None
patent: 3713494 (1987-10-01), None
patent: 40 26 833.0 (1990-08-01), None
patent: 44 47 287 (1996-11-01), None
patent: 4447287 (1996-11-01), None
patent: 0 088 046 (1983-02-01), None
patent: 0 102 324 (1983-07-01), None
patent: 0102324 (1984-03-01), None
patent: 0 152 379 (1985-02-01), None
patent: 0224837 (1986-11-01), None
patent: 0211647 (1987-02-01), None
patent: 0220797 (1987-05-01), None
patent: 0 298 280 (1988-06-01), None
patent: 0280492 (1988-08-01), None
patent: 0 393 707 (1990-04-01), None
patent: 0 475 160 (1991-08-01), None
patent: 0475160 (1992-03-01), None
patent: 0 355 095 (1993-08-01), None
patent: 0674913 (1995-10-01), None
patent: 0704206 (1996-04-01), None
patent: 0707847 (1996-04-01), None
patent: 0 382 716 (1998-01-01), None
patent: 0 995 435 (2000-04-01), None
patent: 9903363 (2000-03-01), None
patent: 0104424 (2002-03-01), None
patent: 0105400 (2002-05-01), None
patent: 61-271204 (1986-12-01), None
patent: 07-324029 (1995-12-01), None
patent: WO-81/02673 (1981-10-01), None
patent: WO 87/01938 (1987-04-01), None
patent: WO 88/07362 (1988-10-01), None
patent: WO 90/09782 (1990-09-01), None
patent: WO 91/04013 (1991-04-01), None
patent: 9203122 (1992-03-01), None
patent: WO 92/05771 (1992-04-01), None
patent: WO-92/22292 (1992-12-01), None
patent: WO 93/19736 (1993-10-01), None
patent: WO 93/19737 (1993-10-01), None
patent: WO-94/26257 (1994-11-01), None
patent: WO-95/35095 (1995-12-01), None
patent: WO-96/29999 (1996-10-01), None
patent: WO-97/21428 (1997-06-01), None
patent: WO 98/06750 (1998-02-01), None
patent: WO-98/07414 (1998-02-01), None
patent: WO 98/17255 (1998-04-01), None
patent: WO 98/30215 (1998-07-01), None
patent: WO 98/33483 (1998-08-01), None
patent: WO-00/13684 (2000-03-01), None
patent: WO-00/25822 (2000-05-01), None
patent: WO-00/38653 (2000-07-01), None
patent: WO-00/44350 (2000-08-01), None
patent: WO-00/50007 (2000-08-01), None
patent: WO-01/01963 (2001-01-01), None
patent: WO-01/12155 (2001-02-01), None
patent: WO-02/07767 (2002-01-01), None
patent: WO-02/11683 (2002-02-01), None
English translation of German Pat. No. 44 47 287 C1 (1996).
Journal of Controlled Release (Apr. 1997) vol. 45, No. 3, table of contents.
G. Cevc et al., Transdermal drug carriers: basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides,J. Contr. Rel., 36, pp. 3-16, 1995.
S. Yuan, et al., Cationic Liposome and Gene Transfer,Progress in Physiological Science, 28(2), pp. 163-165, 1997.
G. Cevc, Transfersomes, Liposomes and Other Lipid Suspensions on the Skin: Permeation Enhancement, Vesicle Penetration, and Transdermal Drug Delivery,Crit. Rev. Ther. Drug Carrier Syst., 13(3&4), pp. 257-388, 1996.
A. Klibanov, et al., Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target,BBA, 1062, pp. 141-148, 1991.
Benner, “The Human Body, The Wonderwork of the Human Body, Structure, Functions, Interactions, Processes and Mechanisms” Weltbild GmbH Augsburg (1995).
Serva, Feinbiochemica Fur Forschung forServa Feinbiochemica GmbH&Co.(1986/1987).
Clark, J.M., Jr., “Experimental Biochemistry” Biochemistry Division, Department of Chemistry, University of Illinois, pp. 47-48.
Patel, H.M. “Liposomes as a Controlled-release System” Biomedical Society Transactions 609th Meeting, Leeds, pp. 513-516.
Fieser, L.F., et al. “Organische Chemie”Hans Ruprecht Hensel, 2nd revised edition, Verlag Chemie GmbH, Weinheim/Bergstr(1968).
Fluka Chemika-BioChemika Catalogue 16 (1988/89).
Roeding, J. “Liposomes and Niosomes in Pharmacy and Cosmetic State of the Art Prospects, Techniques of Visualizing Vesicular Systems, Interaction of Liposomes with the Skin”Training Course No. 105 from May 14 to 16, 1990, MARITIM Hotel Nurnberg, Frauentorgraben 11, 8500 Nurenbwerg.
L. Löbbecke, et al., “Effects of Short-Chain Alcohols On the Phase Behavior And Interdigitation Of Phosphatidylcholine Bilayer Membranes,”Biochimiea et Biophysica Aeta, 1237, pp. 59-69, 1995.
R. Singh, et al., “Liposomally Encapsulated Diclofenac For Sonophoresis Induced Systemic Delivery,”J. Microencapsulation, vol. 12, No. 2, pp. 149-154, 1995.
T. Henmi, et al., “Application of an Oily Gel Formed by Hydrogenated Soybean Phgospholipids as a Percutaneous Absorption-Type Ointment Base,”Chem. Pharm. Bull, 42(3), pp. 651-655, 1994.
M. Foldvari, et al., “Dermal Drug Delivery by Liposome Encapsulation: Clinical and Electron Microscopic Studies,”J. Microencapsulation, vol. 7, No. 4, pp. 479-489, 1990.
M. Foldari, “In Vitro cutaneous and Percutaneous Delivery and in Vivo Efficacy of Tetracaine from Liposomal and Conventional Vehicles,”Pharmaceutical Research, vol. 11, No. 11, 1994.
M. Foldari, “Effect of Vehicle on Topical Liposomal Drug Delivery: Petrolatum Bases,”J. Microencapsulation, vol. 13, No. 5, pp. 589-600, 1996.
M.E. Planas, et al., “Noninvasive Percutaneous Induction of Topical Analgesia by a New Type of Drug Carrier, and Prolongation of Local Pain Insensitivity by Anesthetic Liposomes,”Anesth. Analg., 75, pp. 615-621, 1992.
H. Peters, et al., “Pharmacodynamics of a Liposomal Preparation for Local Anaesthesia,”Arzneim.-Forsch./Drug Res., 45(II), Nr. 12, 1995.
I. Stoye, et al, “Transformation of a Liposomal Dispersion Containing Ibuprofen Lysinate and Phospholipids into Mixed Micelles—Physico-chemical Characterization and Influence on Drug Permeation through Excised Human StratumCorneum,”European Journal of Pharmaceutics and Biopharmaceutics, 46, pp.191-200, 1998.
J. Schramlova, et al., “The Effect of an Antiphlogistic Incorporated in Liposomes on Experimentally Induced Inflammation,”Folia Biologica(Praha), 43, pp. 195-199,

Affiliated with

Also associated with

Rating

Formulation for topical non-invasive application in vivo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulation for topical non-invasive application in vivo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation for topical non-invasive application in vivo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3837540